Economic Evaluation and Resource Use in Thoracentesis and Paracentesis

Overview

This study evaluates the frequency and costs associated with unindicated laboratory tests on paracentesis and thoracentesis specimens from patients with gynecologic cancers.

Background

Paracentesis and thoracentesis are frequently performed procedures in patients with advanced gynecologic cancers experiencing ascites or pleural effusions. Understanding the patterns of unindicated testing can inform future evaluations.

Data Highlights

Key Findings

• 216 patients with gynecologic cancers were analyzed.
• 78% of patients underwent at least one paracentesis; 45% underwent at least one thoracentesis.
• 40% of procedures had laboratory test results sent, with 79% of these containing at least one unindicated test.
• The total cost from unindicated laboratory tests was $1,129,520.
• Non-oncology clinicians had higher odds of ordering unindicated tests compared to oncology clinicians.

Clinical Implications

Clinicians should evaluate the necessity of laboratory tests for paracentesis and thoracentesis in patients with established cancer diagnoses.

Conclusion

The study reveals a prevalence of unindicated laboratory testing in procedures for patients with gynecologic cancers.

Related Resources & Content

1. Economic Assessment of Paravertebral Analgesia Compared to Epidural Analgesia in Minimally Invasive Esophageal Resection: Findings from a Randomized Clinical Trial, 2026 -- https://link.springer.com/article/10.1007/s00464-026-12642-7
2. Economic Evaluation of Laparoscopic Total Gastrectomy Compared to Open Total Gastrectomy for Gastric Cancer, 2024 -- https://link.springer.com/article/10.1007/s00423-024-03562-y
3. Metabolic Shifts During Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Procedures, 2023 -- https://link.springer.com/article/10.1007/s00423-023-02770-2
4. British Thoracic Society Quality Standard for Pleural Disease, 2026 -- https://www.brit-thoracic.org.uk/document-library/quality-standards/pleural-disease/bts-quality-standard-for-pleural-disease
5. Surgical Endoscopy — A Customized Algorithm for Chest Drain Removal After Minimally Invasive Lobectomy: Results from a Prospective Randomized Trial
6. Pleural Effusion: Diagnostic Approach in Adults | AFP
7. ESMO Clinical Practice Guideline Express Update on the management of epithelial ovarian cancer - PMC
8. British Thoracic Society Quality Standard for Pleural Disease
9. ERS/EACTS statement on the management of malignant pleural effusions | European Respiratory Society
10. Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer - PubMed
11. Cancer of the ovary, fallopian tube, and peritoneum: 2025 update - Renz - 2025 - International Journal of Gynecology & Obstetrics - Wiley Online Library
12. Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion: The AMPLE Randomized Clinical Trial - PMC
13. Health economic evaluation results - Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT - NCBI Bookshelf
14. Indwelling Pleural Catheter Drainage Strategy for Malignant Effusion: A Cost-Effectiveness Analysis - PubMed
15. Talc pleurodesis versus indwelling pleural catheter for refractory pleural effusion: a prospective study of survival and complications - PubMed
16. https://nican.hscni.net/wp-content/uploads/2025/08/NICaN-Acute-Oncology-Clinical-Guideline-Jan-22-updated-March-25.pdf
17. Cost-effectiveness of tunneled peritoneal catheters versus repeat paracenteses for recurrent ascites in gynecologic malignancies - ScienceDirect